Navigation Links
Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
Date:1/20/2008

DALLAS Jan. 21, 2008 Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

In todays online issue of Cancer, UT Southwestern doctors analyzed data gathered by the National Cancer Institutes Prostate Cancer Prevention Trial, or PCPT. The trial, which began in October 1993, was designed to test whether finasteride could prevent prostate cancer in men 55 years of age and older. It was stopped early in June 2003 when an analysis showed that finasteride reduced the risk of developing prostate cancer by 25 percent.

UT Southwesterns analysis of the PCPT data indicates that cost effectiveness and quality of life issues associated with taking the drug are not clear cut, said Dr. Yair Lotan, assistant professor of urology and the Cancer studys senior author. The PCPT data show that in addition to preventing prostate cancer, finasteride also reduces urinary-tract symptoms associated with benign prostatic hyperplasia. It also decreased sexual desire and caused impotence in 5 percent of the trial participants. Some PCPT participants who did develop prostate cancer also had high-grade tumors, although there is ongoing debate whether this result might have been due to sampling bias.

Finasteride is currently the only drug that has been shown to prevent prostate cancer in a large randomized trial but is used for this purpose in very few men, Dr. Lotan said. A large number of patients are currently taking over-the-counter supplements to prevent prostate cancer, even though there is no scientific evidence to support these products claims. Its important for patients to be aware of this scientific trial and to ask their doctors if finasteride could benefit them.

In light of all these pros and cons, Dr. Lotan said physicians and patients need to work together closely to weigh how finasteride could affect quality of life on a case-by-case basis.

With the exception of skin cancer, prostate cancer is the most common cancer in American men, Dr. Lotan said. Men who are at low risk for prostate cancer might view taking finasteride as not very cost effective when considering its impact on their quality of life. On the other hand, patients at high risk might see it as cost effective because it lessens their chances of developing prostate cancer.

Because there is some complexity to the PCPT I think doctors hesitate to discuss its results. While Im not advocating for the drug, I think physicians should mention finasteride, especially when their patients are asking questions about ways to prevent prostate cancer. Patients should understand and be aware of the proven science thats out there.


'/>"/>

Contact: Erin Prather Stafford
erin.pratherstafford@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales
2. Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best
3. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
4. Gildas Club Worldwide is a Proven Partner in Quality Cancer Care
5. Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
6. Smoked cannabis proven effective in treating neuropathic pain
7. Benefit of exenatide has not yet been proven
8. Proven Nutrition Provides Energy and Hope to Cancer Fighters
9. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
10. European Summit on Cardiovascular Disease Prevention
11. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
(Date:2/10/2016)... ... 2016 , ... United Benefit Advisors (UBA), the nation’s leading ... its growing list of Partner Firms. S.S. Nesbitt is headquartered in Birmingham, ... and in between. , Harnessing the experience and insights of the agency’s team ...
(Date:2/10/2016)... MI (PRWEB) , ... February 10, 2016 , ... ... Apifiny® across their network of laboratory service centers across the country. Launched ... to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... For additional ... new book , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" ... can improve memory. The book’s publication date is March 16, 2016. A ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable ... find and select appointments via Everseat’s free mobile app. , The partnership gives ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Workrite Ergonomics this ... versatile series of monitor mounts ever. , “Our goal was to develop a ... to install system that we have ever created.” said Darren Hulsey, Product Manager for ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Resolve Therapeutics, LLC, a clinical stage biopharmaceutical ... treatment of lupus and Sjogrens syndrome, today announced ... study in patients with systemic lupus erythematosus (SLE) ... --> --> Data from a ... of RSLV-132 in 32 subjects with SLE demonstrate ...
(Date:2/10/2016)...  Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" ... of its issued and outstanding shares of common stock ... 11, 2016. The Company,s common stock will trade on ... temporary ticker symbol "RCHAD". After 20 trading days, the ... (RCHA).  --> --> ...
(Date:2/10/2016)... , Feb. 10, 2016  The ... Nursing received an in-kind gift from ... a VeinViewer® Vision vein finder for the ... help students as they learn how to ... technology with traditional technique. ...
Breaking Medicine Technology: